So, tonight is the first important news for OSIP: Genentech (DNA) reports Q3 numbers. Then comes Roche & Novartis on Thursday and Merck next Monday. By then we will know how well OSIP did. I hope this quarter is good. This stock has much more potential than what we see in the pps. So, good quartely numbers and a simultaneous approval of Tarceva in Japan would make it jump into the $40+ area. Cross fingers! GLTY
Well, well, well. Have a good day